Skip to main content

Attovia Therapeutics, Inc.

ATTO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0002058707

In the last 90 days, Attovia Therapeutics, Inc. insiders filed 5 open-market purchases and 1 sale; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Key figures

Insider buysLast 90 days, $42.1M in total
5
Insider sellsLast 90 days, $2.25M in total
1
13F holdersQ2 2026
0
13F valueReported value at the end of Q2 2026
$0
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding ATTO, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding ATTO at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Attovia Therapeutics, Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 28, 2026 (view filing)5:38 PM ETAug 5-623 daysWalsh ColinDirectorPPurchase+585.0K$17.58+$10.3M+24.0%3.02M afterAmended2 lotsDuplicate filing
Aug 28, 2026 (view filing)5:38 PM ETAug 523 daysWalsh ColinDirectorSSale−105.8K$21.28−$2.25M−100.0%0 afterAmended23 lotsDuplicate filing
Aug 28, 2026 (view filing)5:38 PM ETAug 523 daysWalsh ColinDirectorPPurchase+105.8K$21.25+$2.25M–105.8K afterAmendedDerivative6 lotsDuplicate filing
Aug 28, 2026 (view filing)5:38 PM ETAug 5-623 daysGoldman Sachs & Co. LLC and 7 othersOther: Former 10% OwnerPPurchase+585.0K$17.58+$10.3M+24.0%3.02M afterAmended2 lots
Aug 28, 2026 (view filing)5:38 PM ETAug 523 daysGoldman Sachs & Co. LLC and 7 othersOther: Former 10% OwnerSSale−105.8K$21.28−$2.25M−100.0%0 afterAmended23 lots
Aug 28, 2026 (view filing)5:38 PM ETAug 523 daysGoldman Sachs & Co. LLC and 7 othersOther: Former 10% OwnerPPurchase+105.8K$21.25+$2.25M–105.8K afterAmendedDerivative6 lots
Aug 10, 2026 (view filing)4:12 PM ETAug 64 daysvenBio Global Strategic Fund IV, L.P.10% OwnerPPurchase+382.4K$17.00+$6.50M+10.1%4.18M after
Aug 7, 2026 (view filing)9:47 PM ETAug 61 dayRedmile Group, LLC and 2 others10% OwnerPPurchase+200.0K$17.00+$3.40M+25.5%982.9K after
Aug 7, 2026 (view filing)9:47 PM ETAug 61 dayRedmile Group, LLC and 2 others10% OwnerPPurchase+400.0K$17.00+$6.80M+51.1%1.18M after
Aug 7, 2026 (view filing)3:45 PM ETAug 61 daySanofi10% OwnerPPurchase+300.0K$17.00+$5.10M+38.3%1.08M after

Top 10 13F holders, Q2 2026

The largest institutional positions in Attovia Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.

View all: Top 10 13F holders, Q2 2026

No institution reported holding ATTO in 13F filings for Q2 2026.